All reviews of published articles are made public. This includes manuscript files, peer review comments, author rebuttals and revised materials. Note: This was optional for articles submitted before 13 February 2023.
Peer reviewers are encouraged (but not required) to provide their names to the authors when submitting their peer review. If they agree to provide their name, then their personal profile page will reflect a public acknowledgment that they performed a review (even if the article is rejected). If the article is accepted, then reviewers who provided their name will be associated with the article itself.
Thank you for revising your manuscript to address the concerns of the reviewers. Reviewer 1 now recommends acceptance and I am satisfied that the comments of reviewer 2 have been addressed. The manuscript is now ready for publication.
ALL THE COMMENTS WERE PROPERLY ADDRESSED BY THE AUTHORS. IT SEEMS FINE NOW.
ALL THE COMMENTS WERE PROPERLY ADDRESSED BY THE AUTHORS. IT SEEMS FINE NOW.
ALL THE COMMENTS WERE PROPERLY ADDRESSED BY THE AUTHORS. IT SEEMS FINE NOW.
Although reviewer 2 has only minor concerns, reviewer 1 notes that the revised manuscript does not incorporate appropriate changes in response to his earlier comments. When submitting your revised manuscript, please include a response to reviewer 1 that explains how your manuscript has been revised. Please also make appropriate changes to address the suggestions of reviewer 2.
My previous review comments were not incorporated into this revised manuscript. I am not satisfied with the current version of the manuscript.
-
-
See attached PDF
-
-
**PeerJ Staff Note:** Please ensure that all review, editorial, and staff comments are addressed in a response letter and that any edits or clarifications mentioned in the letter are also inserted into the revised manuscript where appropriate.
1. What is the current prevalence of AML cases among your Chinese population?
2. What are the OS and RFS of AML cases among your Chinese population?
3. What are the current treatment procedures going on in China for AML?
4. In the GLOBOCAN 2022 data, leukemia is most prevalent in China. What methodologies have you adopted to manage AML cases?
5. Define the role of cytogenetics in the diagnosis of AML.
1. How did you calculate the sample size for this study?
2. Is the FAB Classification you have adopted for the inclusion and exclusion of M3-AML Subtype?
3. How have you designed an NGS panel targeting 56 myeloid-related genes?
4. You have not explained the pipeline for how you did the NGS Analysis.
5. Methodology is unclear; cytogenetics, molecular analysis, and fish all these things were missing.
1. We also workon this gene WT1 on AML. Which variant of mutation have you found in this gene?
2. During NGS Analysis, you did not find any novel variant.
3. What are 0.1, 0.2, 0.3 on the X axis of Figure 1A, a bar graph showing the frequency of mutations in AML.
4. What are the top oncogenic signaling pathways you got by performing NGS Analysis?
The language must be revised. There are many small errors, some errors that makes the sentence unclear. I have comments don some of the references
ok
ok
All text and materials provided via this peer-review history page are made available under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.